TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01696656
Drug: Drug prescription pattern
Approvals — FDA: no, EMA: no, PMDA: no
Description: Type, dosage, administration route and frequency of prescription of all adjuvant pharmacologic agents will be transcribed from hospital records
Study: NCT00617747
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03937544
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will receive lymphodepleting chemotherapies consisting Cyclophosphamide 250mg/m2/day IV(Day -5, Day -4, Day -3 ).
Study: NCT02640313
Drug: 18F-choline PET-MR imaging
Normalized name: Pet-ema
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dynamic and static 18F-choline PET-MR imaging
Study: NCT03846544
Drug: Corifollitoropin alfa (CFA)-double pick up
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the study group, 225 IU of recombinant FSH (rFSH) will continue after the first oocyte retrieval (OR). Antagonist administration will be initiated when at least one follicle measuring ≥14 mm will be present in the ultrasound. If one or more follicles ≥17 mm are observed, patients will undergo a second triggering with human chorionic gonadotropin (hCG) 5000 IU and a second OR will be performed. In case of patients with no follicular development following 10 additional days of rFSH post-OR
Study: NCT02029482
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03108066
Drug: MK-3795
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg twice daily (four 200 mg oral tablets twice daily)
Study: NCT00463008
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT06212284
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doses were gelatine capsules filled with microcrystalline cellulose
Study: NCT00493311
Drug: IV Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV Placebo
Study: NCT00493311
Drug: IV Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous acetaminophen solution 1 g / 100 ml
Study: NCT01869088
Drug: Recombinant Human Adenovirus Type 5 Injection
Normalized name: adenovirus, type 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: After identifying the target artery of HCC, Recombinant Human Adenovirus Type 5 Injection（15.0\*1011vp：0.5ml\*3） will be first infused through the target artery
Study: NCT00860080
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is prepared by dilution of sodium hyaluronate using 0.9% sodium chloride solution. The concentration of sodium hyaluronate is 15 mg/ml after dilution. Placebo will be administered as an abdominal subcutaneous injection of 0.5, 1, and 2 ml respectively.
Study: NCT02957617
Drug: BIIB074
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive an initial dose regimen of 350mg orally twice daily (BID), which may be reduced to 200mg based on tolerability for up to 12 months.
Study: NCT02775292
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01460602
Drug: MTD of Velcade, Nipent and Rituxan established in Part 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: One of the following dose levels will be chosen and used in Part 2:~1. (VAN1) VA= 1.3 mg/m2 IV Days 1, 4, 8, 11 N1= 2 mg/mg2 IV Days 1, 8 375 mg/m2 IV Day 1~2. (VAN2) VA= 1.3 mg/m2 IV Days 1, 4, 8, 11 N1= 4 mg/mg2 IV Days 1, 8 375 mg/m2 IV Day 1~3. (VBN1) VA= 1.5 mg/m2 IV Days 1, 4, 8, 11 N1= 2 mg/mg2 IV Days 1, 8 375 mg/m2 IV Day 1~4. (VBN2) VA= 1.5 mg/m2 IV Days 1, 4, 8, 11 N1= 4 mg/mg2 IV Days 1, 8 375 mg/m2 IV Day 1
Study: NCT03959527
Drug: azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dose: 1g, oral administration
Study: NCT00339833
Drug: Salsalate
Normalized name: Salsalate
DrugBank: Salsalate (DB01399)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The intervention was salsalate (3g/day) for 7 days.
Study: NCT00339833
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identical placebo for 7 days.
Study: NCT00700024
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT00070564
Drug: AC regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT00070564
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00070564
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00460239
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular; double blind; once per week
Study: NCT01535443
Drug: Bromfenac
Normalized name: Bromfenac
DrugBank: Bromfenac (DB00963)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug: Bromfenac Other names: PRO-155
Study: NCT03131726
Drug: Simvastatin 40mg
Normalized name: SIMVASTATIN 40MG TAB
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: see arm description
Study: NCT01407263
Drug: antibiotic prophylaxis
Normalized name: STONE PROPHYLAXIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: One vs. three days of antibiotic prophylaxis at catheter removal
Study: NCT01407263
Drug: Hemostatic Agent
Normalized name: Hemostatic agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: For the patients randomized to routine indwelling HA agent use, the operating surgeon may choose to use either Surgicel™, Surgicel SNoW™, Arista™, FloSeal or surgeon's choice HA directed at the prostatic fossa, ligated dorsal vein complex, or neurovascular bundles. Because there is no standard HA or method of application, the surgeon will apply the HA according to the surgeon's experience and document both the HA used, and the location applied in the operative report. For patients randomized to no routine indwelling HA use, surgeons will only apply a HA if they are unable to achieve hemostasis using traditional means or feel it would be unsafe to complete the operation without using a HA for additional hemostasis. Providers in either arm may use HA as needed provided the intention is not to leave the HA indwelling.
Study: NCT00533221
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0,015 mg/kg/d as one dose s.c. in the evening over one week followed by a 11 week period with 0,03 mg/kg/d s.c. as one dose in the evening
Study: NCT02583022
Drug: Elidel cream 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application
Study: NCT02654158
Drug: High-dose of Fuganlin Oral Liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: less than 1 years old: 10mL each time and three times a day~1\~3 years old: 20mL each time and three times a day~4\~6 years old: 20mL each time and four times a day~7\~12 years old: 20mL each time and five times a day
Study: NCT00650338
Drug: DE-104 ophthalmic solution, low concentration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ocular application
Study: NCT00650338
Drug: DE-104 ophthalmic solution, medium concentration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ocular application
Study: NCT00650338
Drug: DE-104 ophthalmic solution, high concentration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ocular application
Study: NCT00650338
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT02439788
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 500 mg/m2/day x 2 days; for patients \<12 kg the dose is 16.7 mg/kg/day x 2 days; Cyclophospamide will be given daily starting Day -4 prior to administration of GINAKIT cells.
Study: NCT02837302
Drug: Livact
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily dose of 12.45g of branched-chain amino acid containing 3.4g of L-valine, 5.7g of L-leucine, and 2.9g of L-isoleucine over 6 months.
Study: NCT01038154
Drug: Pravastatin
Normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Receive one tablet of 40 mg of pravastatin, orally every 24 hours (at breakfast) for 2 years.
Study: NCT00531947
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo for EMSAM 6mg, 9mg, or 12mg Flexible Dose- 1 patch/24 hours- 12 Week Study
Study: NCT02971293
Drug: AZD8871 100 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: The subjects will receive one dose of AZD8871 100 µg single dose DPI.
Study: NCT02971293
Drug: AZD8871 600 µg
Normalized name: P.G. 600 KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: The subjects will receive AZD8871, 600 µg single dose DPI.
Study: NCT02971293
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The subject will receive Placebo single dose DPI.
Study: NCT00838383
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will begin immediately following cross-clamp release and 12 hours post-CPB.
Study: NCT01468571
Drug: Spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg po daily of spironolactone for 8 weeks. A cross-over study where each subject will receive spironolactone or placebo in a random order for 8 weeks each.
Study: NCT01468571
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each subject will receive placebo or spironolactone for 8 weeks. At the end of week 8, treatment arm for each subject will be blindly switched.~So if a study patient received placebo for the first 8 weeks then he/she will be switched to receive active drug (spironolactone) for the next 8 weeks.
Study: NCT00420628
Drug: loteprednol etabonate/tobramycin opthalmic suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ophthalmic drug: 0.5% loteprednol etabonate with 0.3% tobramycin 4 times a day (QID) days 1-7, 2 times a day (BID) days 8-14. Warm compresses were applied to affected eyes 2 times a day prior to application of study medication.
Study: NCT00420628
Drug: vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical ophthalmic vehicle was applied 4 times a day (QID) days 1-7, 2 times a day (BID) days 8-14. Warm compresses were applied to affected eyes 2 times a day prior to application of study medication.
Study: NCT00023738
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00048633
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04110886
Drug: HSK21542
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose, injection, starting dose of 0.2ug escalating up to 20ug
Study: NCT04110886
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose, injection matching placebo
Study: NCT02385110
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants with central nervous system involvement receive intrathecal methotrexate 12 mg once a week for 5 weeks during the Induction Phase.
Study: NCT03142776
Drug: systemic clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00524706
Drug: S-1, oral Leucovorin, Oxaliplatin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02136901
Drug: NSAID's and Non-surgical Treatment Options
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-prescription drugs, creams, vitamins, and supplements, Prescription or Non-Prescriptions NSAIDs, Non-weight bearing and/or open chain physical therapy or self-administered exercise
Study: NCT02136901
Drug: Intra-Articular Injections with Corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular injection of a corticosteroid, such as 40 mg of Triamcinolone (e.g. Aristocort or Kenalog).
Study: NCT02714205
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study participants will be randomized to transdermal nitroglycerin patch or placebo patch. Participants will wear a study medication patch daily, for 12 weeks.
Study: NCT02637310
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200mg/day, Three times a day orally, 2 tablets once, 7 days
Study: NCT00905567
Drug: Topamax® Tablet 2 x 25 mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02753816
Drug: Placebo Comparator
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04346407
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule daily starting with pre-op cocktail and continued twice daily for three days after surgery
Study: NCT05076604
Drug: Cardioplegia Solution
Normalized name: cardioplegia solutions
Approvals — FDA: no, EMA: no, PMDA: no
Description: The microplegia solution that is standard of care for all cardiac surgery patients, and which all study subjects will receive is:~Induction 240 mL Baxter Cardioplegia Solution 10. 5 mL Potassium Chloride 2 meq/ml (21 meq) 250.5 mL total volume~Maintenance 747 mL Baxter Cardioplegia Solution 3.4 mL Potassium Chloride 2 meq/ml (6.75 meq) 750.4 mL total volume~Subjects will be randomly assigned to 4:1 cardioplegia or nondiluted microplegia.~4:1 cardioplegia consists of 4 parts crystalloid intravenous fluid to one part human blood.~Nondiluted microplegia consists of all parts human blood.
Study: NCT02337634
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taken as two 150mg capsules BID for 2 weeks, then 300mg BID for remainder of the study.
Study: NCT05076604
Drug: Microplegic Solution No. 1
Normalized name: microplegic solution no. 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: The microplegia solution that is standard of care for all cardiac surgery patients, and which all study subjects will receive is:~Induction 240 mL Baxter Cardioplegia Solution 10. 5 mL Potassium Chloride 2 meq/ml (21 meq) 250.5 mL total volume~Maintenance 747 mL Baxter Cardioplegia Solution 3.4 mL Potassium Chloride 2 meq/ml (6.75 meq) 750.4 mL total volume~Subjects will be randomly assigned to 4:1 cardioplegia or nondiluted microplegia.~4:1 cardioplegia consists of 4 parts crystalloid intravenous fluid to one part human blood.~Nondiluted microplegia consists of all parts human blood.
Study: NCT00184002
Drug: Doxorubicin, Rituxan, Cyclophosphamide, Vincristine and Prednisone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cycle 1 Doxil 40 mg/m2 iv day 1 over a minimum of 60 min.~Cyclophosphamide 750 mg/m2 iv day 1 over a minimum of 60 min.~Vincristine 1.4 mg/m2 iv bolus day 1 (2.0 mg maximum).~Prednisone 100 mg po days 1-5.~Cycle 2 until study completion~Doxil 40 mg/m2 iv day 1~Rituxan 375 mg/m2 iv day 1~Cyclophosphamide 750 mg/m2 iv day 1~Vincristine 1.4 mg/m2 iv bolus day 1 (2.0 mg maximum)~Prednisone 100 mg po days 1-5~* 1 cycle = 21 days.~* Continue treatment until 2 cycles beyond documentation of CR for a maximum of 8 cycles.
Study: NCT00828061
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 5 tablets matching placebo (5 x 0 mg) to prednisone. The washout between treatment periods will be approximately 4 weeks
Study: NCT02075008
Drug: QGE031
Approvals — FDA: no, EMA: no, PMDA: no
Description: QGE031 120 mg/mL solution for subcutaneous injection
Study: NCT00408551
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00408551
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04252963
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo of MUCOLASE tablet
Study: NCT02465437
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo q pm (with JBT-101 5 or 20 mg q AM) or placebo bid on Days 1-28. Placebo bid on Days 29-84.
Study: NCT02465437
Drug: Part B Open-Label Extension
Approvals — FDA: no, EMA: no, PMDA: no
Description: JBT-101 20mg bid on Days 1-364
Study: NCT00540644
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 50 mg p.o. BID daily on days 1-21 of each 28 day cycle
Study: NCT01369745
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone 2.7 mg daily
Study: NCT01067417
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taken orally 2x200mg capsules once daily for 48 weeks
Study: NCT00563914
Drug: ferroquine (SSR97193)
Approvals — FDA: no, EMA: no, PMDA: no
Description: associated with artesunate
Study: NCT00441870
Drug: EC0225, for Injection (Folic acid desacetylvinblastine hydrazide conjugate)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose escalation from a starting dose of 0.38mg IV bolus Monday Wednesday and Friday Weeks 1 and 3 of a 4 Week Cycle to the Maximum Tolerated Dose (MTD)
Study: NCT01050322
Drug: Lapatinib Capecitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: The starting dose of capecitabine is 2000 mg/m2/day, to be divided and given twice daily orally, 12 hours apart, for 14 days, every 21 days. A daily dose of Lapatinib is 5 tablets (1250 mg of Lapatinib) taken approximately at the same time each day.
Study: NCT00910845
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (placebo) injected into the detrusor at Day 1.
Study: NCT00084227
Drug: Azithromycin/Chloroquine
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00685360
Drug: Optimized Background Regimen (OBR)
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selection and administration of the treatment medications (i.e., OBRs) was based on World Health Organization (WHO's) Guidelines for the programmatic management of drug-resistant TB, in conjunction with national TB program guidelines in each country.~Study Investigator could change OBR for a participant based on participant's tolerability and drug susceptibility testing (DST) results.
Study: NCT00685360
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets matching 50-mg tablets of delamanid
Study: NCT01678664
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 sessions chemoembolization with 10 mg of lipiodol with 100 mg of doxorubicine
Study: NCT03171597
Drug: Anti-Platelet Drugs
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Including aspirin and clopidogrel, etc.
Study: NCT03171597
Drug: Lipid Regulating Drugs
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mainly including statins
Study: NCT03171597
Drug: Coronary Vasodilator
Normalized name: Glebionis coronaria whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mainly including nitrates
Study: NCT03171597
Drug: Xuefu Zhuyu Decoction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mainly including Peach Kernel, Safflower, Angelica, Bupleurum etc.
Study: NCT03171597
Drug: Gualou Xiebai Banxia Decoction & Danshen Decoction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mainly including Fructus Trichosanthis, Rhizoma Pinelliae, Allium, Salvia Miltiorrhiza etc.
Study: NCT03171597
Drug: Shuanghe Decoction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mainly including Ginseng, Poria, Calamus, Cyperus, Salvia miltiorrhiza, Radix Polygalae etc.
Study: NCT06361186
Drug: Proximod
Normalized name: TRACH ADAPT,PROXIMAL FLO SENS R#1050408
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single and multiple-dose to establish the safety and PK profile
Study: NCT06361186
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo controlled
Study: NCT02497937
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be supplied as blend filled capsule to be administered orally with 240 mL water.
Study: NCT02149264
Drug: Testosterone gel (FE 999303)
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01610869
Drug: BIBF 1120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive either cyclophosphamide (100mg)and oral BIBF 1120 (200mg bd) or cyclophosphamide (100mg) and placebo.
Study: NCT00672633
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corn Oil Pill, 4 pills/day orally for 6 months
Study: NCT00929344
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo capsule administered 1 capsule am and 1 capsule pm for 12 week duration.
Study: NCT04551664
Drug: Best medical management
Approvals — FDA: no, EMA: no, PMDA: no
Description: All the patients enrolled received standard guideline-directed medical therapy including: monitor vital signs, management of blood pressure, glucose and lipids, antithrombotic (antiplatelet or anticoagulant therapy determined by treating physician) therapy if appropriate.
Study: NCT02499120
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for palbociclib will be indistinguishable from the palbociclib capsules and will be supplied as capsules matching in size and color the various palbociclib formulations.~Administered with food on Day 1 to Day 21 followed by 7 days off treatment in a 28-day cycle.
Study: NCT01827592
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02810275
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule received 1 tablet, taking in the morning, during four weeks
Study: NCT01429298
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Attending administers IV opioid of his choosing
Study: NCT01305707
Drug: PHARMACOTHERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacotherapy will remain unchanged since the acute episode to the end of the study. Psychotropics will be obtained as usually from the National Health System and will be prescribed according to data sheet and will have a 15 month duration.
Study: NCT02058589
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 doses administered intramuscularly (IM) in the deltoid region of the non-dominant arm.
Study: NCT03604705
Drug: APX001
Approvals — FDA: no, EMA: no, PMDA: no
Description: APX001
Study: NCT01949142
Drug: Sham
Normalized name: SHAMPOO
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simulated single, intratympanic injection
Study: NCT01900847
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: saline of same volume as appropriate weight based dose of ketamine